与CB-839结合的甲福明特别抑制了KRAS突变卵巢癌的发生
Han Wu1, Jialin Zhang1, Qiujie Wang1
1Department of Obstetrics and Gynecology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
Scientific reports
|February 19, 2025
概括
克拉斯突变重编程卵巢癌的新陈代谢,促进转移. 甲胺和CB-839联合治疗有效地向这种代谢转变,在临床前模型中抑制瘤生长.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 癌症遗传学 癌症遗传学
背景情况:
- KRAS突变与卵巢癌的进展有关.
- 这些突变可以驱动代谢重编程,增强转移潜力.
- 了解这些代谢变化对于开发向疗法至关重要.
研究的目的:
- 为了研究KRAS突变卵巢癌中的代谢重编程.
- 探索甲胺和一种谷氨酸酶1抑制剂 (CB-839) 的联合作用机制.
- 在临床前模型中评估这种组合的治疗疗效.
主要方法:
- 在KRAS突变细胞与野生类型卵巢癌细胞中对葡萄糖和谷氨酸代谢相关酶表达的比较分析.
- 对有氧氧化能力的评估.
- 实验室和体内研究评估了单独和组合使用的甲胺和CB-839的作用.
主要成果:
- KRAS突变卵巢癌细胞表现出关键的葡萄糖和谷氨酸代谢酶的高表达.
- 这些细胞显示有氧氧化能力增加.
- 甲胺和CB-839联合治疗显著抑制了KRAS突变细胞中的增殖和有氧氧化,在小鼠模型中效果优于单一药物.
结论:
- 在卵巢癌中,KRAS突变诱导了显著的代谢重编程,其特征是葡萄糖和谷氨酸代谢的增强.
- 甲福明和CB-839的组合有效地准了这些代谢漏洞.
- 这种组合疗法显示出对抗KRAS突变卵巢癌的前临床疗效有希望.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.6K
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
13.6K
相关概念视频
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
